Pacific Biosciences of California, Inc. carries a market capitalization of 428.63M, placing it among publicly traded companies globally. Its enterprise value stands at 826.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 428.63M |
| Enterprise Value | 826.31M |
Pacific Biosciences of California, Inc. currently has 310.49M shares outstanding.
| Shares Outstanding | 310.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
The price-to-sales ratio is 2.49, and the price-to-book ratio stands at -0.15.
| PE Ratio | N/A |
| PS Ratio | 2.49 |
| PB Ratio | -0.15 |
| P/TBV Ratio | -1.21 |
| P/FCF Ratio | -3.89 |
| P/OCF Ratio | -3.57 |
| EV / Sales | 5.16 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Pacific Biosciences of California, Inc. maintains a current ratio of 5.65, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29,728.99, indicating elevated leverage, while an interest coverage ratio of -23.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.65 |
| Quick Ratio | 4.67 |
| Debt / Equity | 29,728.99 |
| Debt / EBITDA | -4.36 |
| Interest Coverage | -23.20 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -15.65 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.90 |
| Income Tax | 804,000.00 |
| Effective Tax Rate | N/A |
Pacific Biosciences of California, Inc.'s stock has declined approximately -18.3432% over the past 52 weeks. The 50-day moving average sits at 1.43, while the 200-day moving average is 1.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.3432% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 1.71 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Pacific Biosciences of California, Inc. generated 160.03M in revenue and converted that into -128.58M in net income, yielding earnings per share of -0.43. EBITDA reached -161.38M, while operating income came in at -179.08M.
| Revenue | 160.03M |
| Gross Profit | 59.99M |
| Operating Income | -179.08M |
| Pretax Income | -127.77M |
| Net Income | -128.58M |
| EBITDA | -161.38M |
| EBIT | -179.08M |
| Earnings Per Share (EPS) | -0.43 |
Pacific Biosciences of California, Inc. holds 275.96M in cash and equivalents against 703.39M in total debt, resulting in a net debt position of 587.83M. Total book value stands at -2.70B, with working capital of 304.16M providing operational flexibility.
| Cash & Cash Equivalents | 275.96M |
| Total Debt | 703.39M |
| Net Debt | 587.83M |
| Equity (Book Value) | -2.70B |
| Book Value Per Share | -8.95 |
| Working Capital | 304.16M |
Pacific Biosciences of California, Inc. produced -111.84M in operating cash flow over the past twelve months. After subtracting -9.37M in capital expenditures, free cash flow totaled -121.21M - equivalent to -0.40 per share.
| Operating Cash Flow | -111.84M |
| Capital Expenditures | -9.37M |
| Free Cash Flow | -121.21M |
| FCF Per Share | -0.40 |
Pacific Biosciences of California, Inc. operates with a gross margin of 37.49, reflecting its pricing power and cost economics. The operating margin of -111.90 and net profit margin of -80.34 provide insight into operational efficiency.
| Gross Margin | 37.49 |
| Operating Margin | -111.90 |
| Pretax Margin | -79.84 |
| Profit Margin | -80.34 |
| EBITDA Margin | -100.84 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.73 |
| FCF Yield | -25.69 |
Pacific Biosciences of California, Inc. posts an Altman Z-Score of -8.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -8.24 |